The response of advanced prostatic cancer to a new non-steroidal antiandrogen: results of a multicenter open phase II study of Casodex. European/Australian Co-operative Group.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 2094607.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Casodex is a non-steroidal antiandrogen which shows marked peripheral selectivity in animals. As an antiandrogen, it has been shown in a dose ranging and an open phase II study to have fewer side-effects than traditional non-steroidal antiandrogens and to be very well tolerated. In the open phase II study, the 50 mg dose was used in 127 evaluable patients who have been treated for up to 1 year. Overall response (i.e. partial response [PR]) was 50% with a further 33% showing stabilization of disease.
Medical subject headings
- Anilides
- Prostatic Neoplasms